EUVIMEDEUVIMED entdecken
Crossref

Time to genetic testing in Dravet syndrome: Trends, barriers, and opportunities for improvement

Ross A Carson iD, John E Maldonado Pacheco iD, Christina Briscoe Abath iD, Christelle Moufawad El Achkar iD

Epilepsia · 2026

DOI: 10.1111/epi.18666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Ross A Carson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Testing, Epilepsies, Myoclonic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Genetic testing can be necessary in the early diagnosis or confirmation of Dravet syndrome (DS). Despite major advances in availability of genetic testing, several barriers to timely testing persist. These include clinician recognition of the disease in its early stages and health disparities. Early diagnosis of DS has a growing list of management implications, including antiseizure medication selection, appropriate counseling regarding prognosis, access to resources, and clinical trial access.

Methods

To understand the barriers to early genetic testing in DS, we performed a retrospective chart review of patients with DS due to SCN1A variants and analyzed factors hypothesized to affect time to testing. Factors including the initial clinical presentation and health disparities were correlated with length of time to testing from the first documented seizure.

Results

Factors significantly correlated with time to testing included absence of early status epilepticus and the need for an English‐language interpreter. Interestingly, neither race/ethnicity nor a composite social deprivation index were significantly correlated with delays in genetic testing in our population. Significance We identified significant factors associated with delay to genetic testing in DS. Purposefully addressing these factors through education and resources will likely be important for continued improvement in early and equitable diagnosis for patients with DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingEpilepsies, MyoclonicHumansMaleFemaleRetrospective StudiesNAV1.1 Voltage-Gated Sodium ChannelChildChild, PreschoolAdolescentInfant

Stichwörter der Autor:innen

SCN1ADravet syndromeepilepsy geneticsgenetic testinghealth equity

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, human

Autor:innen und Institutionen

  • Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Pediatrics, University of Colorado, Anschutz Campus, Aurora, Colorado, USA.
  • Department of Neurology, University of Colorado, Anschutz Campus, Aurora, Colorado, USA.

ORCID-Profile: Ross A Carson, John E Maldonado Pacheco, Christina Briscoe Abath, Christelle Moufawad El Achkar

Zitieren

APA

Carson, R. A., Maldonado Pacheco, J. E., Abath, C. B., & El Achkar, C. M. (2026). Time to genetic testing in Dravet syndrome: Trends, barriers, and opportunities for improvement. Epilepsia. https://doi.org/10.1111/epi.18666

Vancouver

Carson RA, Maldonado Pacheco JE, Abath CB, El Achkar CM. Time to genetic testing in Dravet syndrome: Trends, barriers, and opportunities for improvement. Epilepsia. 2026. doi:10.1111/epi.18666

BibTeX
@article{Carson2026,
  author = {Carson, Ross A and Maldonado Pacheco, John E and Abath, Christina Briscoe and El Achkar, Christelle Moufawad},
  title = {Time to genetic testing in Dravet syndrome: Trends, barriers, and opportunities for improvement},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1111/epi.18666}
}
Kostenlos starten →